Phio Pharmaceuticals director David Deming buys $10,066 in stock

Phio Pharmaceuticals Director David Deming boosted his stake in the company through two rounds of stock purchases totaling $10,066. These transactions transpired over the course of two days, with each share priced between $0.838 and $0.8395. The purchases were made in the wake of the stock trading near its lowest point in the past 52 weeks, which is currently $0.75 - a decrease of approximately 41% over the last year.

On November 10, 2026, Deming bought 6,800 shares at an average price of $0.8395 per share, with the shares acquired in several transactions costing anywhere from $0.8079 to $0.8600. The following day, November 11, 2026, he bought an additional 5,200 shares at an average cost of $0.838 per share, with prices per share for these shares ranging from $0.8269 to $0.8600.

Deming's total direct ownership in Phio Pharmaceuticals Corp. common stock is now 49,800 shares, which also includes shares tied to unvested restricted stock units. For those looking for more in-depth analysis, InvestingPro provides 13 ProTips for PHIO, including Fair Value assessments and financial health indicators to evaluate this $9.7 million market cap biotech firm.